ABSTRACT
Cancer is not a disease but a series of diseases. Without pre-clinical and clinical research, it would be difficult to continue following. Nivolumab + Ipilimumab provides a better overall survival for melanoma. Prostate cancer SPARTAN shows a trend to benefit. In endometrial cancer, IMvigor130 tested chemo + immunotherapy in patients eligible/ineligible for chemo-therapy but today is not a standard; NABUCCO neoadjuvant Ipilimumab/Nivolumab was tolerated in high-risk urothelial carcinoma. In breast cancer, MONALEESA-3/7 data represent the largest evidence for survival for cyclin-dependent-kinases inhibitor without a match. Ribociclib shows significant benefit in overall survival in MONALEESA-3/7. Abemaciclib shows significant benefit in overall survival in MONARCH 2. CDICAB inhibitors are selection drugs in advanced-luminal-treatment first/second lines. The Nivolumab + Ipilimumab confirms a strong activity in cervical cancer. Pembrolizumab + Lenvatinib show excellent results in endometrial cancer. Ovarian cancer first-line Veliparib shows excellent results with a rise in progression-free survival in all patients. Surgically ablated patients are excluded. The primary objective is met. Results are got in BRCA mutation 94and homologous recombination deficiency subgroups. Central arm exists with relative volume change. In lung cancer internal survival, Atezolizumab increases survival vs. chemotherapy PDL1/TC3/IC3. Nivolumab + Ipilimumab improves overall survival vs. chemotherapy.
